CD33 inhib 
Welcome,         Profile    Billing    Logout  
 13 Companies  15 Products   15 Products   46 Diseases   8 Trials   488 News 


«12345678910111213...1617»
  • ||||||||||  Journal:  Acute myeloid leukemia transformed to a targetable disease. (Pubmed Central) -  Feb 9, 2021   
    These new drugs led to the change of the landscape of the treatment of AML and transforming this disease to a targetable one. We aimed in this paper to review the implications of each new target, the mechanisms of action of these new drugs and we discuss all the studies leading to the approval of these new drugs in their indications according to each target.
  • ||||||||||  [VIRTUAL] Aggressive Thyroid Cancer is Associated With Suppressor Circulating Immunophenotype (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_2112;    
    This circulating immunophenotype may serve as a biomarker for cancer prognosis and guide the selection and development of novel immunotherapies for advanced thyroid cancer. Unless otherwise noted, all poster abstracts presented at ENDO 2021 are embargoed until 11 AM Eastern on Saturday, March 20.
  • ||||||||||  [VIRTUAL] NK Cell Enhancement Using an Anti-CD16/IL-12/Anti-CD33 Killer Engager () -  Jan 27, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_3050;    
    We also explored the biological relevance and found that treatment with an IL-12 TriKE induced NK cells to produce a more restricted repertoire of cytokines with a stronger IFNg profile, rescued cytotoxicity and IFNg production from exhaustion, and induced dendritic cell maturation. These characteristics demonstrate that the cytokine present in the TriKE can robustly change the nature of the NK cell response and highlight a new immunotherapeutic strategy via the utilization of TriKEs that focuses on evasion of exhaustion and induction of adaptive immunity.
  • ||||||||||  [VIRTUAL] NK Cell Enhancement Using an Anti-CD16/IL-12/Anti-CD33 Killer Engager () -  Jan 27, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_3049;    
    We also explored the biological relevance and found that treatment with an IL-12 TriKE induced NK cells to produce a more restricted repertoire of cytokines with a stronger IFNg profile, rescued cytotoxicity and IFNg production from exhaustion, and induced dendritic cell maturation. These characteristics demonstrate that the cytokine present in the TriKE can robustly change the nature of the NK cell response and highlight a new immunotherapeutic strategy via the utilization of TriKEs that focuses on evasion of exhaustion and induction of adaptive immunity.
  • ||||||||||  [VIRTUAL] NK Cell Enhancement Using an Anti-CD16/IL-12/Anti-CD33 Killer Engager () -  Jan 27, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_3048;    
    We also explored the biological relevance and found that treatment with an IL-12 TriKE induced NK cells to produce a more restricted repertoire of cytokines with a stronger IFNg profile, rescued cytotoxicity and IFNg production from exhaustion, and induced dendritic cell maturation. These characteristics demonstrate that the cytokine present in the TriKE can robustly change the nature of the NK cell response and highlight a new immunotherapeutic strategy via the utilization of TriKEs that focuses on evasion of exhaustion and induction of adaptive immunity.
  • ||||||||||  [VIRTUAL] NK Cell Enhancement Using an Anti-CD16/IL-12/Anti-CD33 Killer Engager () -  Jan 27, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_3047;    
    We also explored the biological relevance and found that treatment with an IL-12 TriKE induced NK cells to produce a more restricted repertoire of cytokines with a stronger IFNg profile, rescued cytotoxicity and IFNg production from exhaustion, and induced dendritic cell maturation. These characteristics demonstrate that the cytokine present in the TriKE can robustly change the nature of the NK cell response and highlight a new immunotherapeutic strategy via the utilization of TriKEs that focuses on evasion of exhaustion and induction of adaptive immunity.
  • ||||||||||  [VIRTUAL] NK Cell Enhancement Using an Anti-CD16/IL-12/Anti-CD33 Killer Engager () -  Jan 27, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_3046;    
    We also explored the biological relevance and found that treatment with an IL-12 TriKE induced NK cells to produce a more restricted repertoire of cytokines with a stronger IFNg profile, rescued cytotoxicity and IFNg production from exhaustion, and induced dendritic cell maturation. These characteristics demonstrate that the cytokine present in the TriKE can robustly change the nature of the NK cell response and highlight a new immunotherapeutic strategy via the utilization of TriKEs that focuses on evasion of exhaustion and induction of adaptive immunity.
  • ||||||||||  Journal:  Does the CD33 rs3865444 Polymorphism Confer Susceptibility to Alzheimer's Disease? (Pubmed Central) -  Jan 23, 2021   
    The overall results do not support the hypothesis that CD33 rs3865444 polymorphism increases the risk of AD. The results also suggest that the identification of functional variants in CD33 that are indisputably correlated with AD may be an important factor to investigate in future genetic screening studies.
  • ||||||||||  [VIRTUAL] Evaluation of a Next-Generation Sequencing-Based Solution for Chimerism Monitoring () -  Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2047;    
    All data generated by the NGS method showed high reproducibility between runs. The data generated by the NGS-based chimerism approach evaluated in this study combined the accuracy, reproducibility and sensitivity of an optimal method for routine chimerism testing at clinical labs, potentially enabling early detection of disease relapse.
  • ||||||||||  [VIRTUAL] Evaluation of a Next-Generation Sequencing-Based Solution for Chimerism Monitoring () -  Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2046;    
    All data generated by the NGS method showed high reproducibility between runs. The data generated by the NGS-based chimerism approach evaluated in this study combined the accuracy, reproducibility and sensitivity of an optimal method for routine chimerism testing at clinical labs, potentially enabling early detection of disease relapse.
  • ||||||||||  [VIRTUAL] Evaluation of a Next-Generation Sequencing-Based Solution for Chimerism Monitoring () -  Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2045;    
    All data generated by the NGS method showed high reproducibility between runs. The data generated by the NGS-based chimerism approach evaluated in this study combined the accuracy, reproducibility and sensitivity of an optimal method for routine chimerism testing at clinical labs, potentially enabling early detection of disease relapse.
  • ||||||||||  [VIRTUAL] Evaluation of a Next-Generation Sequencing-Based Solution for Chimerism Monitoring () -  Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2044;    
    All data generated by the NGS method showed high reproducibility between runs. The data generated by the NGS-based chimerism approach evaluated in this study combined the accuracy, reproducibility and sensitivity of an optimal method for routine chimerism testing at clinical labs, potentially enabling early detection of disease relapse.
  • ||||||||||  [VIRTUAL] Evaluation of a Next-Generation Sequencing-Based Solution for Chimerism Monitoring () -  Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2043;    
    All data generated by the NGS method showed high reproducibility between runs. The data generated by the NGS-based chimerism approach evaluated in this study combined the accuracy, reproducibility and sensitivity of an optimal method for routine chimerism testing at clinical labs, potentially enabling early detection of disease relapse.
  • ||||||||||  [VIRTUAL] Post-Allogeneic HCT Microchimerism Monitoring Solution with High Accuracy and Sensitivity () -  Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_862;    
    AlloHeme has high accuracy and sensitivity detecting down to 1 patient cell in 1,000 donor cells in blood and bone marrow samples. Given previously published data on the association of increase in patient cells post-HCT with increased risk of disease relapse, AlloHeme may be particularly suited for HCT patient surveillance to help identify recurrence of primary disease in hematologic cancer patients with or without known cancer-associated genetic determinants.
  • ||||||||||  [VIRTUAL] Post-Allogeneic HCT Microchimerism Monitoring Solution with High Accuracy and Sensitivity () -  Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_861;    
    AlloHeme has high accuracy and sensitivity detecting down to 1 patient cell in 1,000 donor cells in blood and bone marrow samples. Given previously published data on the association of increase in patient cells post-HCT with increased risk of disease relapse, AlloHeme may be particularly suited for HCT patient surveillance to help identify recurrence of primary disease in hematologic cancer patients with or without known cancer-associated genetic determinants.
  • ||||||||||  [VIRTUAL] Post-Allogeneic HCT Microchimerism Monitoring Solution with High Accuracy and Sensitivity () -  Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_860;    
    AlloHeme has high accuracy and sensitivity detecting down to 1 patient cell in 1,000 donor cells in blood and bone marrow samples. Given previously published data on the association of increase in patient cells post-HCT with increased risk of disease relapse, AlloHeme may be particularly suited for HCT patient surveillance to help identify recurrence of primary disease in hematologic cancer patients with or without known cancer-associated genetic determinants.
  • ||||||||||  [VIRTUAL] Post-Allogeneic HCT Microchimerism Monitoring Solution with High Accuracy and Sensitivity () -  Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_859;    
    AlloHeme has high accuracy and sensitivity detecting down to 1 patient cell in 1,000 donor cells in blood and bone marrow samples. Given previously published data on the association of increase in patient cells post-HCT with increased risk of disease relapse, AlloHeme may be particularly suited for HCT patient surveillance to help identify recurrence of primary disease in hematologic cancer patients with or without known cancer-associated genetic determinants.
  • ||||||||||  [VIRTUAL] Post-Allogeneic HCT Microchimerism Monitoring Solution with High Accuracy and Sensitivity () -  Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_858;    
    AlloHeme has high accuracy and sensitivity detecting down to 1 patient cell in 1,000 donor cells in blood and bone marrow samples. Given previously published data on the association of increase in patient cells post-HCT with increased risk of disease relapse, AlloHeme may be particularly suited for HCT patient surveillance to help identify recurrence of primary disease in hematologic cancer patients with or without known cancer-associated genetic determinants.
  • ||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
    [VIRTUAL] Use of next generation sequencing to identify AML with germline predisposition; an essential diagnostic test () -  Jan 5, 2021 - Abstract #BSHI2020BSH-I_56;    
    He was recruited to the MRC AML15 trial and treated with a non‐transplant protocol (2 cycles of FLAG‐Ida induction and 3 cycles of high dose cytarabine consolidation)...As the initial working diagnosis was therapy‐related AML he was commenced on Vyxeos chemotherapy with a plan for allogeneic SCT at CR1...Beyond implications for prognosis, family screening and family planning the presence of a germline mutation is particularly important to establish in the context of a planned related donor SCT. New pathways must therefore be developed to allow timely access to Clinical Genetics.
  • ||||||||||  Journal:  Erratum: Generation of Human Neurons and Oligodendrocytes from Pluripotent Stem Cells for Modeling Neuron-Oligodendrocyte Interactions. (Pubmed Central) -  Dec 31, 2020   
    We can maintain the co-cultures in acceptable health condition for up to 6 weeks and observe that the synapse number and other neuronal attributes plateau around the fifth week. Of note, astrocytes and microglia are not present in our preparations and their absence can be documented by checking the expression of specific markers (Figure 3D). The iOPCs express a good number of well-characterized genes that can potentially respond to and mediate the activity-dependent signals from neighboring neurons, in a paracrine (e.g. neurotrophins and metabolites) and/or a synaptic manner (Figure 3E and 3F).